Selecta Biosciences, Inc. SELB
0.88 +0.88
Day range unavailable
52-week range unavailable
News
globenewswire.com Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024
globenewswire.com Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting…
globenewswire.com Selecta Biosciences Announces Merger with Cartesian Therapeutics – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease –
globenewswire.com Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic…
zacks.com Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue Estimates Selecta Biosciences, Inc. (SELB) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.06 per share a year ago.
globenewswire.com Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics – Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 –
seekingalpha.com Selecta Biosciences, Inc. (SELB) Q1 2023 Earnings Call Transcript Selecta Biosciences, Inc. (NASDAQ:SELB ) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Blaine Davis - CFO Carsten Brunn - CEO, President & Director Peter Traber - Chief…
benzinga.com Earnings Scheduled For May 4, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
globenewswire.com Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update WATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic…
pennystocks.com 4 Hot Penny Stocks To Watch With News This Week Penny stocks to watch this week. The post 4 Hot Penny Stocks To Watch With News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
seekingalpha.com Selecta Biosciences, Inc. (SELB) Q4 2022 Earnings Call Transcript Selecta Biosciences, Inc. (NASDAQ:SELB ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Blaine Davis - Chief Financial Officer Carsten Brunn - President, Chief…
benzinga.com Earnings Scheduled For March 2, 2023 Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
pennystocks.com Best Penny Stocks To Buy? 4 Stocks Under $3 To Watch This Week Penny stocks under $3 to watch this week. The post Best Penny Stocks To Buy?
investorplace.com The 7 Best Biotech Stocks to Buy for February 2023 While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility…
seekingalpha.com Selecta: Despite Challenges, Dissolve Topline Data Could Move The Stock I covered SELB twice. The gout phase 3 trial has certain challenges.
seekingalpha.com Selecta Biosciences, Inc. (SELB) Q3 2022 Earnings Call Transcript Selecta Biosciences, Inc. (NASDAQ:SELB ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Carsten Brunn - President and Chief Executive Officer Kevin Tan - Chief…
benzinga.com Earnings Scheduled For November 3, 2022 Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
pennystocks.com What The Stock Market Did Today & Top Penny Stocks To Watch Now Hot penny stocks to watch & what happened in the stock market today. The post What The Stock Market Did Today & Top Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and…
globenewswire.com Selecta Biosciences to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic…
globenewswire.com Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic…
seekingalpha.com Selecta: ImmTOR Could Change Autoimmune Disorder Treatment Landscape Results for both studies from the DISSOLVE phase 3 program, using SEL-212 for the treatment of patients with chronic refractory gout, are expected in Q1 of 2023. Potential to restore immune tolerance…
benzinga.com Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday Gainers
seekingalpha.com Selecta Biosciences, Inc's (SELB) CEO Carsten Brunn on Q2 2022 Results - Earnings Call Transcript Selecta Biosciences, Inc. (NASDAQ:SELB ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Kevin Tan – Chief Financial Officer Carsten Brunn – President and Chief…- benzinga.com Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate Here's a roundup of top developments in the biotech space over the last 24 hours:
benzinga.com Earnings Scheduled For August 4, 2022 Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
globenewswire.com Selecta Biosciences to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic…- benzinga.com 63 Biggest Movers From Yesterday Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the…
benzinga.com Earnings Scheduled For May 5, 2022 Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 435 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 431 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 466 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 166 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 454 stocks hit new 52-week lows.- benzinga.com Earnings Scheduled For March 10, 2022 Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 729 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 524 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 313 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 147 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks
- benzinga.com The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Here's a roundup of top developments in the biotech space over the last 24 hours:
- benzinga.com Earnings Scheduled For November 9, 2021 Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.
- benzinga.com 77 Biggest Movers From Yesterday Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 on Thursday after the company announced it is expanding its blockchain business to engage in…
- benzinga.com Earnings Scheduled For August 12, 2021 Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
- benzinga.com 61 Biggest Movers From Yesterday Gainers
- benzinga.com 60 Biggest Movers From Yesterday Gainers Lizhi Inc. (NASDAQ: LIZI) shares surged 57.6% to close at $6.84 on Wednesday.
- benzinga.com 41 Stocks Moving In Wednesday's Mid-Day Session Gainers Asensus Surgical, Inc. (NYSE: ASXC) shares surged 34.4% to $2.7282. HC Wainwright & Co. initiated coverage on Asensus Surgical with a Buy rating and announced a price target of $4.
- benzinga.com Earnings Scheduled For May 13, 2021 Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.